User login
Dr. Tadeusz Robak and Dr. Michael Hallek discuss data suggesting that adding rituximab to fludarabine and cyclophosphamide improves survival in advanced chronic lymphocytic leukemia. Bob Finn of Elsevier Global Medical News (EGMN) reports from the annual meeting of the American Society of Hematology.
Dr. Tadeusz Robak and Dr. Michael Hallek discuss data suggesting that adding rituximab to fludarabine and cyclophosphamide improves survival in advanced chronic lymphocytic leukemia. Bob Finn of Elsevier Global Medical News (EGMN) reports from the annual meeting of the American Society of Hematology.
Dr. Tadeusz Robak and Dr. Michael Hallek discuss data suggesting that adding rituximab to fludarabine and cyclophosphamide improves survival in advanced chronic lymphocytic leukemia. Bob Finn of Elsevier Global Medical News (EGMN) reports from the annual meeting of the American Society of Hematology.